Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real‐world study | Synapse
March 15, 2026Open Access
Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real‐world study
Puntos clave
The aim of the research is to assess the effectiveness and safety of lecanemab in the Chinese Alzheimer's disease population.
Multicenter real-world study
Evaluation of lecanemab efficacy and safety
Measure plasma p-tau217 levels as a biomarker
Lecanemab was effective in treating Alzheimer's disease in the observed population
Lecanemab was well tolerated by patients
Plasma p-tau217 shows potential as a treatment-response biomarker
Resumen
Lecanemab was effective and well tolerated in real-world Chinese patients. Plasma p‑tau217 may serve as a sensitive, minimally invasive treatment-response biomarker.